SLC5A2 and heart failure: As shown in Figure 3, pooled result of the 5 trials (29, 30, 43–45) revealed that SGLT2 inhibitors significantly reduced the composite of first hospitalization for heart failure or cardiovascular death compared to placebo in patients with HFpEF (HR:0.78, 95% CI: [0.70, 0.87], P<0.00001, I2 = 0%).